# Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

> **NCT04085250** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 264 (actual)

## Conditions studied

- Stage III Non-small-cell Lung Cancer

## Interventions

- **OTHER:** Neoadjuvant therapy
- **OTHER:** Chemotherapy concurrent with radiotherapy
- **RADIATION:** Radiotherapy
- **DRUG:** Nivolumab
- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT04085250
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-28
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04085250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04085250, "Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04085250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*